[go: up one dir, main page]

MX2023008333A - Nanomateriales. - Google Patents

Nanomateriales.

Info

Publication number
MX2023008333A
MX2023008333A MX2023008333A MX2023008333A MX2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A MX 2023008333 A MX2023008333 A MX 2023008333A
Authority
MX
Mexico
Prior art keywords
nanomaterials
nanoparticles
preparations
methods
present disclosure
Prior art date
Application number
MX2023008333A
Other languages
English (en)
Inventor
Cory Dane Sago
Gregory Lawrence Hamilton
Original Assignee
Beam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beam Therapeutics Inc filed Critical Beam Therapeutics Inc
Publication of MX2023008333A publication Critical patent/MX2023008333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación describe composiciones, preparaciones, nanopartículas (tales como nanopartículas lipídicas) y/o nanomateriales y métodos para usarlos.
MX2023008333A 2021-01-20 2022-01-19 Nanomateriales. MX2023008333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163139734P 2021-01-20 2021-01-20
PCT/US2022/012941 WO2022159463A1 (en) 2021-01-20 2022-01-19 Nanomaterials

Publications (1)

Publication Number Publication Date
MX2023008333A true MX2023008333A (es) 2023-08-21

Family

ID=82549752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008333A MX2023008333A (es) 2021-01-20 2022-01-19 Nanomateriales.

Country Status (10)

Country Link
US (2) US12059477B2 (es)
EP (1) EP4281050A4 (es)
JP (1) JP2024502954A (es)
KR (1) KR20230131863A (es)
CN (1) CN116761888A (es)
AU (1) AU2022210313A1 (es)
CA (1) CA3203742A1 (es)
IL (1) IL303846A (es)
MX (1) MX2023008333A (es)
WO (1) WO2022159463A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103542A4 (en) 2020-01-09 2024-02-14 Guide Therapeutics, LLC NANOMATERIALS
CN116847853A (zh) 2021-01-20 2023-10-03 比姆医疗股份有限公司 包括可生物降解的特征的纳米材料
AU2022210313A1 (en) 2021-01-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials
AU2022210317A1 (en) * 2021-01-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising an ionizable lipid
AU2023311822A1 (en) 2022-07-20 2025-01-09 Beam Therapeutics Inc. Nanomaterials comprising triols
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110977A (en) 1990-02-14 1992-05-05 Eastman Kodak Company Ester-containing quaternary ammonium salts as adhesion improving toner charge agents
AU9319398A (en) 1997-09-19 1999-04-05 Sequitur, Inc. Sense mrna therapy
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
WO2014136086A1 (en) * 2013-03-08 2014-09-12 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
PL3083556T3 (pl) 2013-12-19 2020-06-29 Novartis Ag Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
ES2969956T3 (es) * 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US10369122B2 (en) 2015-05-21 2019-08-06 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
ES2969082T3 (es) 2015-09-17 2024-05-16 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
EP3649142A4 (en) 2017-07-04 2021-09-01 Intocell, Inc. JOINTS WITH SPLITABLE LINKER AND USES THEREOF
EP3704262B1 (en) 2017-10-30 2024-03-20 Georgia Tech Research Corporation Multiplexed analysis of materials for tissue delivery
WO2019099501A1 (en) 2017-11-14 2019-05-23 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
TW202028170A (zh) 2018-10-02 2020-08-01 美商英特利亞醫療公司 可離子化胺脂質
IL314386A (en) 2018-12-05 2024-09-01 Intellia Therapeutics Inc amine modified lipids
EP3911302B1 (en) 2019-01-17 2025-09-10 Georgia Tech Research Corporation Drug delivery systems containing oxidized cholesterols
JP7693552B2 (ja) 2019-02-13 2025-06-17 ビーム セラピューティクス インク． アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法
KR20250152113A (ko) 2019-04-25 2025-10-22 인텔리아 테라퓨틱스, 인크. 이온화 가능한 아민 지질 및 지질 나노입자
JP2022536112A (ja) 2019-06-05 2022-08-12 ガイド セラピューティクス，インコーポレーテッド 組織送達のための材料の分析
US20220273566A1 (en) 2019-07-29 2022-09-01 Georgia Tech Research Corporation Nanomaterials containing constrained lipids and uses thereof
EP4004207A4 (en) 2019-07-29 2023-08-23 Georgia Tech Research Corporation OLIGONUCLEOTIDE ANTAGONISTS FOR RNA-GUIDED GENO EDITING
KR20220113737A (ko) 2019-12-06 2022-08-16 가이드 테라퓨틱스 엘엘씨 나노물질
EP4103542A4 (en) 2020-01-09 2024-02-14 Guide Therapeutics, LLC NANOMATERIALS
CA3203457A1 (en) 2020-12-21 2022-06-30 Beam Therapeutics Inc. Nanomaterials comprising acetals
EP4262819A4 (en) 2020-12-21 2024-12-04 Beam Therapeutics Inc. NANOMATERIALS WITH ESTER-BOUND ACETALS
CN116685332A (zh) 2020-12-21 2023-09-01 比姆医疗股份有限公司 包括碳酸盐的纳米材料
AU2022210313A1 (en) 2021-01-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials
AU2022210317A1 (en) 2021-01-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising an ionizable lipid
WO2022159421A1 (en) 2021-01-20 2022-07-28 Beam Therapeutics Inc. Ionizable lipids for nanomaterials
CN116847853A (zh) 2021-01-20 2023-10-03 比姆医疗股份有限公司 包括可生物降解的特征的纳米材料
EP4452930A1 (en) 2021-12-20 2024-10-30 Beam Therapeutics Inc. Ionizable amine and ester lipids and lipid nanoparticles
WO2023121964A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
WO2023121975A1 (en) 2021-12-20 2023-06-29 Beam Therapeutics Inc. Ionizable amine lipids and lipid nanoparticles
EP4452925A1 (en) 2021-12-20 2024-10-30 Beam Therapeutics Inc. Nanomaterial comprising diamines
AU2022421708A1 (en) 2021-12-20 2024-06-20 Beam Therapeutics Inc. Nanomaterials comprising tetravalent lipid compounds

Also Published As

Publication number Publication date
US20220249693A1 (en) 2022-08-11
IL303846A (en) 2023-08-01
US12059477B2 (en) 2024-08-13
EP4281050A4 (en) 2025-05-21
US20250041441A1 (en) 2025-02-06
KR20230131863A (ko) 2023-09-14
CA3203742A1 (en) 2022-07-28
AU2022210313A1 (en) 2023-06-29
CN116761888A (zh) 2023-09-15
JP2024502954A (ja) 2024-01-24
EP4281050A1 (en) 2023-11-29
WO2022159463A1 (en) 2022-07-28
AU2022210313A9 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
MX2023008333A (es) Nanomateriales.
MX2023007137A (es) Nanomateriales que comprenden acetales unidos a ésteres.
MX2025000643A (es) Nanomateriales que comprenden trioles
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2023005697A (es) Composiciones y metodos para la estabilizacion de vacunas de arnm en nanoparticulas lipidicas.
MX2024013597A (es) Composiciones de nanoparticulas lipidicas para suministro de agentes biologicamente activos
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
MX2025003080A (es) Conjugados de il-15, y sus usos
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
WO2020172420A3 (en) Stable anhydrous cleanser concentrate formulation and method of making same
EP4279071A3 (en) Novel cannabinoid formulations
ZA202309516B (en) Anti-ccr8 antibodies
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2023008328A (es) Nanomateriales que comprenden una caracteristica biodegradable.
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
GB2568181A (en) Wheat
MX2020008125A (es) Composiciones que comprenden berberina.
WO2018189661A3 (en) Methods and compounds for treating diabetes
MX2021009108A (es) Nanoproductos microbicidas y microbiostaticos de amplio espectro y formulaciones, preparaciones y metodos para su uso.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
AU2020235128A8 (en) Transparent or semitransparent inverse microlatices of polyacrylamide as oil emulsion drift reducing agent